Salinas-Casado Jesus, Méndez-Rubio Santiago, Esteban-Fuertes Manuel, Gómez-Rodríguez Antonio, Vírseda-Chamorro Miguel, Luján-Galán Marcos, Rituman Grupo
Servicio de Urología. Hospital Clínico San Carlos. Madrid. España.
Servicio de Urología. Hospital Universitario Sanitas La Moraleja. Madrid. España.
Arch Esp Urol. 2018 Mar;71(2):169-177.
To compare the efficacy and safety of dietary supplement "Manosar®" composed of D-mannose (2 g), 24 h prolonged release, associated with Proanthocyanidin (PAC) (140 mg), ursolic acid (7.98 mg), A, C, and D vitamins and the oligoelement zinc, versus 240 mg of PAC in recurrent urinary tract infections (UTI), for a designed follow-up of 24 weeks, in women.
A multicenter randomized experimental double-blind study was carried out. The study was approved by review board of "Complejo Hospitalario de Toledo" (Spain), and all patients gave informed consent. A total of 150 women with non complicated UTI were screened for participation. Valid data was obtained from 93, with mean age of 48 years. Fortyfour patients were assigned to the Manosar® group and 51 patients to the PAC group. Patients were followed during six months. A previous UTI was defined based on a combination of symptoms and a positive reactive urine trip. Confirmation of a new UTI was based on symptoms, reactive urine strip and urine culture.
Thirty-three patients (35%) had an UTI during the six months follow-up. The percentage of UTI of the Manosar® group during this period was 24%, while the percentage of the PAC group was 45% (p〈0.05). The disease-free time for the Manosar® group was 95 days, while this time was 79 days for the PAC group. The incidence of side effects was low. Diarrhea was the most frequent side-effect in both groups.
Manosar® (oral once a day) is more effective than single dose PAC (240 mg daily orally) to prevent recurrent UTI in women.
比较由D-甘露糖（2克，24小时缓释）、原花青素（PAC）（140毫克）、熊果酸（7.98毫克）、维生素A、C和D以及微量元素锌组成的膳食补充剂“Manosar®”与240毫克PAC对复发性尿路感染（UTI）女性患者的疗效和安全性，设计随访期为24周。
开展一项多中心随机实验双盲研究。该研究经西班牙“托莱多综合医院”审查委员会批准，所有患者均签署了知情同意书。共筛选了150例无并发症的UTI女性患者参与研究。从93例患者获得有效数据，平均年龄48岁。44例患者被分配到Manosar®组，51例患者被分配到PAC组。对患者进行为期六个月的随访。既往UTI根据症状和尿试纸阳性反应综合判定。新UTI的确认基于症状、尿试纸反应和尿培养。
在六个月的随访期间，33例患者（35%）发生了UTI。在此期间，Manosar®组UTI的发生率为24%，而PAC组为45%（p〈0.05）。Manosar®组的无病时间为95天，而PAC组为79天。副作用发生率较低。腹泻是两组中最常见的副作用。
Manosar®（每日口服一次）在预防女性复发性UTI方面比单剂量PAC（每日口服240毫克）更有效。
